Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

One Health genomic surveillance identified high-risk carbapenem-resistant ST821 clones of <i>Acinetobacter baumannii</i> in Nigerian clinical and community settings.

Microbial genomics·2026
Same author

Investigation of the essential role of capsular polysaccharide in serotype 1 <i>Streptococcus pneumoniae</i>.

Frontiers in cellular and infection microbiology·2026
Same author

Investigating prognostic classifications of preexisting multiple long-term conditions for health outcomes 1 year after COVID-19 hospitalization: A UK prospective observational study.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Disease-Attenuated Pneumococcal Biosynthesis Gene Mutants Invade the Mucosal Epithelium and Induce Innate Immunity.

The Journal of infectious diseases·2026
Same author

Biofilm formation during pneumococcal carriage imprints naturally acquired humoral immunity.

bioRxiv : the preprint server for biology·2025
Same author

Symptoms, risk of future exacerbations, and response to long-term macrolide treatment in bronchiectasis: an observational study.

The Lancet. Respiratory medicine·2025
Same journal

Letter to the Editor: 'Life expectancy of UK physicians in the early 21st century: An analysis of 1,000 fellows from the Royal College of Physicians' Munk's Roll'.

Clinical medicine (London, England)·2026
Same journal

Finerenone Exposure and Ischemic Stroke in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Propensity Score-Matched Cohort Study.

Clinical medicine (London, England)·2026
Same journal

Prevalence and predictive factors of chronic kidney disease among individuals with cardiometabolic risk factors: A multicenter cross sectional study, North East Ethiopia.

Clinical medicine (London, England)·2026
Same journal

Authors' response to Dr Lucy Williams' letter to the Editor: 'Life expectancy of UK physicians in the early 21st century: An analysis of 1,000 fellows from the Royal College of Physicians' Munk's Roll'.

Clinical medicine (London, England)·2026
Same journal

Resident doctor workforce wellbeing worldwide: lessons between the United Kingdom and Australia.

Clinical medicine (London, England)·2026
Same journal

Premature ventricular complexes.

Clinical medicine (London, England)·2026
See all related articles

Related Experiment Video

Updated: May 14, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Community-acquired pneumonia.

Jeremy S Brown1

  • 1University College London. jeremy.brown@ucl.ac.uk

Clinical Medicine (London, England)
|January 25, 2013
PubMed
Summary
This summary is machine-generated.

Community-acquired pneumonia (CAP) is a common, serious infection. Rising incidence and mortality highlight the need for better risk assessment and targeted treatments for this lung infection.

More Related Videos

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

Related Experiment Videos

Last Updated: May 14, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 17, 2014

Area of Science:

  • Pulmonology
  • Infectious Diseases
  • Critical Care Medicine

Background:

  • Community-acquired pneumonia (CAP) is a leading cause of hospital admissions, primarily caused by Streptococcus pneumoniae, influenza A, Mycoplasma pneumoniae, and Chlamydophila pneumoniae.
  • Key risk factors for CAP include advanced age, smoking, and pre-existing comorbidities, contributing to increasing incidence and complications like intensive care unit (ICU) admission.

Discussion:

  • Despite generally straightforward diagnosis and treatment, CAP presents complexities, with surprisingly high mortality rates observed in some regions.
  • Physicians require a robust understanding of CAP management due to its increasing prevalence and associated complications.

Key Insights:

  • Biomarker utilization for improved risk stratification and personalized management holds promise for enhancing patient outcomes.
  • Targeting inflammation associated with CAP may offer therapeutic benefits.

Outlook:

  • Urgent research into host-microbial interactions within the lungs is crucial.
  • Clinical trials evaluating novel management and preventative strategies are essential to reduce CAP morbidity and mortality.